RegenXBio (RGNX) AI Stock Analysis

• Market Cap: $511.64M
• Dividend Yield: N/A
• Average Volume (3M): 1.27M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.13
• Revenue Growth: 80.70%
• EPS Growth: 46.66%
• Country: US
• Employees: 353
• Sector: Healthcare
• Sector Strength: 58
• Industry: Biotechnology
• EPS (TTM): 0.12
• Shares Outstanding: 50,160,350
• 10 Day Avg. Volume: 1,336,581
• 30 Day Avg. Volume: 1,269,856
• PEG Ratio: 0.01
• Price to Book (P/B): 1.90
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.11
• Enterprise Value/Market Cap: 1.91
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: 8.14
• Enterprise Value/Ebitda: -1.28
• 1Y Price Target: $34.78
• Price Target Upside: 275.19% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 11

• Rating: 66 Neutral
• Price Target: $10.50 ▲(13.27%Upside)

RegenXBio's overall stock score is driven by strong technical momentum and positive earnings call sentiment, highlighting clinical advancements and strategic partnerships. Financial challenges and valuation concerns weigh down the score, but the recent corporate event provides a positive funding outlook, enhancing the company's financial stability.

Positive Factors

Clinical Trial Progress

RGX-202 improved North Star Ambulatory Assessment (NSAA) and timed function tests, exceeding external natural history control.

Financial Stability

RGNX announced a royalty transaction with Healthcare Royalty, extending cash runway into early-27.

Safety Profile

Safety data is clean with no serious adverse events or adverse events of special interest across 12 dosed patients.

Negative Factors

Revenue Uncertainty

Uncertainty around Zolgensma revenue trajectory and patent duration remains.

Stock Performance

Shares are down over 10% despite functional benefit optically superior to Elevidys, as bears argue small number of patients and optical regression in NSAA make differentiation versus SRPT unclear.

RegenXBio Business Overview & Revenue Model

Company Description

RegenXBio Inc. (RGNX) is a biotechnology company focused on the development, commercialization, and licensing of gene therapy products. The company leverages its proprietary NAV Technology Platform to develop treatments for a range of retinal, metabolic, and neurodegenerative diseases. RegenXBio's core offerings include gene therapy product candidates designed to address unmet medical needs by delivering therapeutic genes to patients using viral vectors.

How the Company Makes Money

RegenXBio generates revenue primarily through licensing agreements and collaborations related to its NAV Technology Platform. The company licenses its technology to other pharmaceutical and biotechnology companies, which in turn develop and commercialize gene therapy products. RegenXBio receives upfront payments, milestone payments, and royalties on sales of products developed using its platform. Additionally, the company engages in strategic partnerships and collaborations to co-develop therapies, sharing both the costs and profits. These partnerships often provide funding for research and development, contributing significantly to RegenXBio's earnings.

RegenXBio Financial Statement Overview

Summary

RegenXBio faces significant financial challenges with ongoing net losses despite healthy gross profit margins. The balance sheet shows moderate strength with manageable debt levels, but the negative net profit margin and cash flow issues remain concerning. Improvement in free cash flow is a positive sign, yet profitability is needed to leverage equity effectively.

Income Statement

RegenXBio's income statement shows significant challenges with profitability. The company's gross profit margin is healthy at approximately 76.55% TTM, but it is overshadowed by persistent net losses, as indicated by a negative net profit margin of -100.62% TTM. Revenue growth shows volatility, with a recent increase of 88.04% from the previous year, yet this is not translating into profits. EBIT and EBITDA margins are also negative, reflecting ongoing operational losses.

Balance Sheet

The balance sheet reveals a moderate financial position with a debt-to-equity ratio of 0.29 TTM, indicating a manageable debt level relative to equity. The equity ratio is 55.84% TTM, suggesting a decent proportion of assets financed by equity. However, the company's return on equity remains negative due to sustained net losses, highlighting the need for improved profitability to leverage equity effectively.

Cash Flow

RegenXBio's cash flow statement presents a mixed picture. Operating cash flow is negative, reflecting cash burn from operations. Despite this, the free cash flow has shown improvement, with a reduction in negative free cash flow by 50.47% from the previous year. The ratio of operating cash flow to net income is above 1, indicating that the company is effective in converting net income (albeit negative) into operating cash flow, yet free cash flow remains a concern.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
156.72M	83.33M	90.24M	112.72M	470.35M	154.57M
	Gross Profit
119.95M	49.76M	53.03M	58.18M	418.51M	118.85M
	EBIT
-157.36M	-233.35M	-268.13M	-262.88M	159.98M	-119.23M
	EBITDA
-128.92M	-198.23M	-239.46M	-244.24M	169.54M	-96.83M
	Net Income Common Stockholders
-157.69M	-227.10M	-263.49M	-280.32M	127.84M	-111.25M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
267.87M	234.69M	275.26M	364.64M	457.44M	475.74M
	Total Assets
490.93M	465.99M	573.97M	833.27M	1.11B	708.16M
	Total Debt
79.85M	82.03M	89.29M	94.80M	86.68M	72.65M
	Net Debt
-50.26M	24.51M	54.77M	-2.15M	-258.53M	-265.77M
	Total Liabilities
216.73M	206.34M	262.23M	317.07M	349.61M	330.41M
	Stockholders Equity
274.20M	259.65M	311.74M	516.20M	764.30M	377.75M
Cash Flow		Free Cash Flow
-86.94M	-175.56M	-228.37M	-238.21M	134.70M	-80.93M
	Operating Cash Flow
-84.04M	-173.13M	-218.41M	-207.49M	218.88M	-54.06M
	Investing Cash Flow
135.01M	103.45M	190.94M	-11.93M	-406.64M	122.76M
	Financing Cash Flow
-33.84M	92.68M	-34.97M	-28.84M	195.25M	200.21M

RegenXBio Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 9.27
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RGNX, the sentiment is Neutral. The current price of 9.27 is below the 20-day moving average (MA) of 9.54, above the 50-day MA of 8.40, and above the 200-day MA of 8.82, indicating a neutral trend. The MACD of 0.34 indicates Positive momentum. The RSI at 50.26 is Neutral, neither overbought nor oversold. The STOCH value of 65.56 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for RGNX.

RegenXBio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
RGNX	66 Neutral	$511.64M	―	-47.44%	―	80.70%	46.66%
VERV	58 Neutral	$569.63M	―	-34.26%	―	271.44%	26.65%
AMLX	57 Neutral	$483.14M	―	-83.24%	―	-100.32%	-197.69%
TSHA	54 Neutral	$698.29M	―	-159.34%	―	-48.97%	69.32%
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
IVA	51 Neutral	$473.84M	―	344.74%	―	-47.32%	-26.67%
ERAS	34 Underperform	$430.60M	―	-45.82%	―	―	10.38%

RegenXBio Corporate Events

RegenXBio Holds 2025 Annual Stockholders Meeting

At REGENXBIO Inc.’s 2025 Annual Meeting of Stockholders held on May 30, 2025, several key proposals were voted on. Four individuals were elected as Class I directors to serve until 2028, and PricewaterhouseCoopers LLP was ratified as the independent public accounting firm for the year. Additionally, stockholders approved the executive compensation plan and decided to hold annual advisory votes on this matter. The 2025 Equity Incentive Plan was also approved.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.

RegenXBio Secures $250M Royalty Monetization Deal

On May 16, 2025, REGENXBIO Inc. announced a strategic royalty monetization agreement with HealthCare Royalty Management, LLC, securing up to $250 million in non-dilutive funding through a limited recourse royalty bond. This agreement provides immediate capital of $150 million, extending the company’s cash runway into early 2027 and supporting its late-stage gene therapy programs. The deal allows REGENXBIO to leverage anticipated royalties from products like ZOLGENSMA® and potential future milestones, positioning the company to accelerate commercial preparations and maintain its leadership in gene therapy.

The most recent analyst rating on (RGNX) stock is a Buy with a $39.00 price target. To see the full list of analyst forecasts on RegenXBio stock, see the RGNX Stock Forecast page.